Kathleen B Digre1, Beau B Bruce2, Michael P McDermott2, Kristin M Galetta2, Laura J Balcer2, Michael Wall2. 1. From the Moran Eye Center (K.B.D.), University of Utah, Salt Lake City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; Departments of Biostatistics and Computational Biology and Neurology (M.P.M.), and Center for Human Experimental Therapeutics, University of Rochester Medical Center, NY; Department of Neurology (K.M.G.), University of Pennsylvania School of Medicine, Philadelphia; Departments of Neurology and Ophthalmology (L.J.B.), New York University; and Department of Ophthalmology and Visual Sciences (M.W.), University of Iowa Carver College of Medicine, Iowa City. kathleen.digre@hsc.utah.edu. 2. From the Moran Eye Center (K.B.D.), University of Utah, Salt Lake City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; Departments of Biostatistics and Computational Biology and Neurology (M.P.M.), and Center for Human Experimental Therapeutics, University of Rochester Medical Center, NY; Department of Neurology (K.M.G.), University of Pennsylvania School of Medicine, Philadelphia; Departments of Neurology and Ophthalmology (L.J.B.), New York University; and Department of Ophthalmology and Visual Sciences (M.W.), University of Iowa Carver College of Medicine, Iowa City.
Abstract
OBJECTIVE: The study purpose was to examine vision-specific and overall health-related quality of life (QOL) at baseline in Idiopathic Intracranial Hypertension Treatment Trial patients who were newly diagnosed and had mild visual loss. We also sought to determine the associations between vision-specific QOL scores and visual symptoms, visual function, pain, headache-related disability, and obesity. METHODS: We assessed QOL using the 36-Item Short Form Health Survey, National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), and 10-Item NEI-VFQ-25 Neuro-Ophthalmic Supplement. We compared these results with those of previously reported idiopathic intracranial hypertension (IIH) QOL studies. We assessed relationships between QOL and other clinical characteristics. RESULTS: Among 165 participants with IIH (161 women and 4 men with a mean age ± SD of 29.2 ± 7.5 years), vision-specific QOL scores were reduced compared with published values for disease-free controls. Scores of participants were comparable to published results for patients with multiple sclerosis and a history of optic neuritis. A multiple linear regression model for the NEI-VFQ-25 composite score found that perimetric mean deviation in the best eye, visual acuity in the worst eye, visual symptoms, and pain symptoms (headache, neck pain), but not obesity, were independently associated with QOL. CONCLUSIONS: IIH affects QOL at time of diagnosis even in patients with mild visual impairment. Vision-specific QOL in patients with newly diagnosed IIH may be as decreased as that for patients with other neuro-ophthalmic disorders. IIH treatment should target visual loss and other symptoms of increased intracranial pressure associated with reduced QOL. Reduced QOL does not simply reflect obesity, an underlying IIH risk factor.
OBJECTIVE: The study purpose was to examine vision-specific and overall health-related quality of life (QOL) at baseline in Idiopathic Intracranial Hypertension Treatment Trial patients who were newly diagnosed and had mild visual loss. We also sought to determine the associations between vision-specific QOL scores and visual symptoms, visual function, pain, headache-related disability, and obesity. METHODS: We assessed QOL using the 36-Item Short Form Health Survey, National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25), and 10-Item NEI-VFQ-25 Neuro-Ophthalmic Supplement. We compared these results with those of previously reported idiopathic intracranial hypertension (IIH) QOL studies. We assessed relationships between QOL and other clinical characteristics. RESULTS: Among 165 participants with IIH (161 women and 4 men with a mean age ± SD of 29.2 ± 7.5 years), vision-specific QOL scores were reduced compared with published values for disease-free controls. Scores of participants were comparable to published results for patients with multiple sclerosis and a history of optic neuritis. A multiple linear regression model for the NEI-VFQ-25 composite score found that perimetric mean deviation in the best eye, visual acuity in the worst eye, visual symptoms, and pain symptoms (headache, neck pain), but not obesity, were independently associated with QOL. CONCLUSIONS: IIH affects QOL at time of diagnosis even in patients with mild visual impairment. Vision-specific QOL in patients with newly diagnosed IIH may be as decreased as that for patients with other neuro-ophthalmic disorders. IIH treatment should target visual loss and other symptoms of increased intracranial pressure associated with reduced QOL. Reduced QOL does not simply reflect obesity, an underlying IIH risk factor.
Authors: Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Michael Wall; Mark J Kupersmith; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Michael P McDermott Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Tanya G K Bentley; Mari Palta; Adam J Paulsen; Dasha Cherepanov; Nancy Cross Dunham; David Feeny; Robert M Kaplan; Dennis G Fryback Journal: Qual Life Res Date: 2011-03-10 Impact factor: 4.147
Authors: Deborah I Friedman; Peter A Quiros; Prem S Subramanian; Luis J Mejico; Shan Gao; Michael McDermott; Michael Wall Journal: Headache Date: 2017-07-28 Impact factor: 5.887
Authors: Michael Wall; Mark J Kupersmith; Matthew J Thurtell; Heather E Moss; Elizabeth Ann Moss; Peggy Auinger Journal: Am J Ophthalmol Date: 2017-01-17 Impact factor: 5.258
Authors: Nieves Martín-Begué; Eduard Mogas; Charlotte Wolley Dod; Silvia Alarcón; María Clemente; Ariadna Campos-Martorell; Ana Fábregas; Diego Yeste Journal: J Clin Res Pediatr Endocrinol Date: 2020-10-02
Authors: Rory J Piper; Aristotelis V Kalyvas; Adam M H Young; Mark A Hughes; Aimun A B Jamjoom; Ioannis P Fouyas Journal: Cochrane Database Syst Rev Date: 2015-08-07